Clinical Trial Update: A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating two doses of AP-472 as an add-on to levodopa in Parkinson disease patients with motor fluctuations, and the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AP-472
• levodopa (levodopa)

Snippet

Sponsor: Appello Pharmaceuticals, Inc. | Conditions: Parkinson Disease | Phase 2 | Status: RECRUITING